In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting.
about
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational ModificationsUnraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic ProteinsImmunogenicity of mAbs in non-human primates during nonclinical safety assessmentImmunogenicity of therapeutic proteins: influence of aggregation.Phosphatidylserine Converts Immunogenic Recombinant Human Acid Alpha-Glucosidase to a Tolerogenic Form in a Mouse Model of Pompe Disease.Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting.Effect of Biophysical Properties of Phosphatidylserine Particle on Immune Tolerance Induction Toward Factor VIII in a Hemophilia A Mouse Model.
P2860
Q26738810-7423A11C-29F8-4601-8B5C-C61460111AECQ28066498-10AD1217-A26D-4D16-8A0E-F10EFF1F0683Q30390955-842BC232-1F69-4E8F-86E6-2BC980475C83Q38126938-92F398AB-010A-490E-80DD-ECDDF82446E4Q39527140-7EBDC992-B4F0-4E42-A541-259BBA9FE004Q41353938-081BE443-8113-4FD1-BAED-44E813E11782Q41651439-9E29EEB6-0638-48D1-8CAA-A6566DE20564
P2860
In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting.
@ast
In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting.
@en
In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting.
@nl
type
label
In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting.
@ast
In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting.
@en
In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting.
@nl
prefLabel
In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting.
@ast
In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting.
@en
In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting.
@nl
P2860
P1476
In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting.
@en
P2093
Puneet Gaitonde
Sathy V Balu-Iyer
P2860
P304
P356
10.1007/978-1-61779-012-6_16
P407
P577
2011-01-01T00:00:00Z